Image Place holder

Sean Dineen, MD

Specialty: Surgery
Sub Specialty: Complex General Surgical Oncology, General Surgery
Program: Gastrointestinal Oncology


Cancer Focus: Appendiceal (Appendix) Cancer, Colorectal Cancer, Esophageal Cancer, Gallbladder Cancer, Gastrointestinal Carcinoid Tumor, GIST (Gastrointestinal Stromal Tumor), Liver Cancer, Mesothelioma, Neuroendocrine Tumor, Pancreatic Cancer, Small Intestine Cancer, Stomach (Gastric) Cancer

Dr. Sean Dineen is an Assistant Member of the Department of Gastrointestinal Oncology at Moffitt Cancer Center. Dr. Dineen has a particular interest in the treatment of patients with metastatic disease, including carcinomatosis. In particular, he focuses on patients that have developed peritoneal spread of disease and the application of heated intraperitoneal chemotherapy (HIPEC) in the treatment of this advanced process. Dr. Dineen’s research focuses on identifying how the tumor and the local environment interact to promote metastatic disease. Dr. Dineen is a native of Lexington, KY. He earned his medical degree from the University of Louisville. He completed residency in general surgery at UT Southwestern in Dallas, which included a research fellowship focused on the tumor microenvironment. He subsequently completed a fellowship in Complex General Surgical Oncology at MD Anderson Cancer Center, where he earned the Clinical Excellence award from the Department of Surgery. Dr. Dineen joins Moffitt from the University of Kentucky, where he was previously the Medical Director of the Multidisciplinary Clinic at Markey Cancer Center. Dr. Dineen has an excellent publication record and has presented nationally and internationally on GI and peritoneal diseases. He is a member of the American College of Surgeons (ACS), the Americas Hepato-Pancreato-Biliary Association (AHPBA) and the Society for Surgeons of the Alimentary Tract (SSAT).

Education & Training

Board Certification:

  • Surgery - Complex General Surgical Oncology
  • Surgery - General Surgery


  • UT Southwestern - Therapeutic Oncology Research - Therapeutic Oncology
  • MD Anderson Cancer Center - Complex General Surgical Oncology


  • UT Southwestern - General Surgery

Medical School:

  • University of Louisville College of Medicine - MD
Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.


  • Powers BD, Felder SI, Imanirad I, Dessureault S, Dineen SP. The Impact of Histologic Subtype on Receipt of Adjuvant Chemotherapy and Overall Survival in Stage III Colon Cancer: a Retrospective Cohort Analysis. J Gastrointest Cancer. 2021 Jun.52(2):719-727. Pubmedid: 32743731.
  • Lee RM, Gamboa AC, Turgeon MK, Zaidi MY, Kimbrough C, Leiting J, Grotz T, Lee AJ, Fournier K, Powers B, Dineen S, Baumgartner JM, Veerapong J, Mogal H, Clarke C, Wilson G, Patel S, Hendrix R, Lambert L, Pokrzywa C, Abbott DE, LaRocca CJ, Raoof M, Greer J, Johnston FM, Staley CA, Cloyd JM, Maithel SK, Russell MC. A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. J Surg Oncol. 2021 Jan.123(1):187-195. Pubmedid: 33002202. Pmcid: PMC7957345.
  • Broman KK, Baez H, Mihelic E, Zhu S, Dineen S, Fleming JB, Anaya DA, Pimiento JM. Combined use of advanced practice providers and care pathways reduces the duration of stay after surgery for gastrointestinal malignancies. Surgery. 2021 Apr.169(4):852-858. Pubmedid: 32713756.
  • Eng OS, Blakely AM, Lafaro KJ, Fournier KF, Fackche NT, Johnston FM, Dineen S, Powers B, Hendrix R, Lambert LA, Ronnekleiv-Kelly S, Walle KV, Grotz TE, Leiting JL, Patel SH, Dhar VK, Baumgartner JM, Lowy AM, Clarke CN, Mogal H, Zaidi MY, Staley CA, Kimbrough C, Cloyd JM, Lee B, Raoof M. Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. J Surg Oncol. 2020 Oct.122(5):980-985. Pubmedid: 32627199.
  • Roife D, Powers BD, Zaidi MY, Staley CA, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Lee B, Blakely A, Greer J, Johnston FM, Laskowitz D, Dessureault S, Dineen SP. CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Ann Surg Oncol. 2020 Oct.27(13):4996-5004. Pubmedid: 33073341.
  • Pointer DT, Saeed S, Naffouje SA, Mehta R, Hoffe SE, Dineen SP, Fleming JB, Fontaine JP, Pimiento JM. Outcomes of 350 Robotic-assisted Esophagectomies at a High-volume Cancer Center: A Contemporary Propensity-score Matched Analysis. Ann Surg. 2020 Nov. Pubmedid: 33201093.
  • Turgeon MK, Gamboa AC, Lee RM, Zaidi MY, Kimbrough C, Grotz T, Fournier K, Powers B, Dineen S, Veerapong J, Clarke C, Mogal H, Patel SH, Lambert L, Ronnekleiv-Kelly S, Raoof M, Fackche N, Greer JB, Staley CA, Cloyd JM, Maithel SK, Winer JH. The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Ann Surg Oncol. 2020 May.27(13):4894-4907. Pubmedid: 32378087. Pmcid: PMC7644621.
  • Beal EW, Ahmed A, Grotz T, Leiting J, Fournier KF, Lee AJ, Dineen S, Dessureault S, Baumgartner JM, Veerapong J, Clarke C, Strong E, Maithel SK, Zaidi MY, Patel S, Dhar V, Hendrix R, Lambert L, Johnston F, Fackche N, Raoof M, LaRocca C, Ronnekleiv-Kelly S, Pokrzywa C, Pawlik TM, Abdel-Misih S, Cloyd JM. Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. Am J Surg. 2020 Mar.219(3):478-483. Pubmedid: 31558307.
  • Beal EW, Suarez-Kelly LP, Kimbrough CW, Johnston FM, Greer J, Abbott DE, Pokrzywa C, Raoof M, Lee B, Grotz TE, Leiting JL, Fournier K, Lee AJ, Dineen SP, Powers B, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Russell MC, Zaidi MY, Patel SH, Dhar V, Lambert L, Hendrix RJ, Hays J, Abdel-Misih S, Cloyd JM. Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. J Clin Med. 2020 Mar.9(3). Pubmedid: 32164300. Pmcid: PMC7141272.
  • Gamboa AC, Lee RM, Turgeon MK, Zaidi MY, Kimbrough CW, Grotz TE, Leiting J, Fournier K, Lee AJ, Dineen SP, Powers BD, Veerapong J, Baumgartner JM, Clarke CN, Mogal H, Patel SH, Lee TC, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Eng OS, Johnston FM, Greer J, Cloyd JM, Maithel SK, Staley CA. Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol. 2020 Jul.27(13):4980-4995. Pubmedid: 32696303. Pmcid: PMC7988818.
  • Balbona J, Chen L, Malafa MP, Hodul PJ, Dineen SP, Mehta R, Mhaskar RS, Pimiento JM. Outcomes of Gastric Resection in the Establishment of a Comprehensive Oncologic Robotic Program. J Surg Res. 2020 Aug.252:30-36. Pubmedid: 32222591.
  • Powers BD, Dineen SP. ASO Author Reflections: To Redo or Not to Redo, That is the Question: Assessing the Slings and Arrows of Repeat CRS/HIPEC in Patients with Recurrent or Progressive Peritoneal Carcinomatosis. Ann Surg Oncol. 2020 Apr.27(13):4892-4893. Pubmedid: 32318947.
  • Powers BD, Felder S, Veerapong J, Baumgartner JM, Clarke C, Mogal H, Staley CA, Maithel SK, Patel S, Dhar V, Lambert L, Hendrix RJ, Abbott DE, Pokrzywa C, Raoof M, Lee B, Johnston FM, Greer J, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Imanirad I, Dessureault S, Dineen SP. Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. Ann Surg Oncol. 2020 Apr.27(13):4883-4891. Pubmedid: 32318945.
  • Zaidi MY, Lee RM, Gamboa AC, Speegle S, Cloyd JM, Kimbrough C, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Dessureault S, Kelly KJ, Kotha NV, Clarke C, Gamblin TC, Patel SH, Lee TC, Hendrix RJ, Lambert L, Ronnekleiv-Kelly S, Pokrzywa C, Blakely AM, Lee B, Johnston FM, Fackche N, Russell MC, Maithel SK, Staley CA. Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. Ann Surg Oncol. 2019 Oct.27(1):156-164. Pubmedid: 31602579. Pmcid: PMC7195626.
  • Wiseman JT, Kimbrough C, Beal EW, Zaidi MY, Staley CA, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers B, Veerapong J, Baumgartner JM, Clarke C, Patel SH, Dhar V, Hendrix RJ, Lambert L, Abbott DE, Pokrzywa C, Raoof M, Lee B, Fackche N, Greer J, Pawlik TM, Abdel-Misih S, Cloyd JM. Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. Ann Surg Oncol. 2019 Oct.27(3):783-792. Pubmedid: 31659645.
  • Gamboa AC, Zaidi MY, Lee RM, Speegle S, Switchenko JM, Lipscomb J, Cloyd JM, Ahmed A, Grotz T, Leiting J, Fournier K, Lee AJ, Dineen S, Powers BD, Lowy AM, Kotha NV, Clarke C, Gamblin TC, Patel SH, Lee TC, Lambert L, Hendrix RJ, Abbott DE, Vande Walle K, Lafaro K, Lee B, Johnston FM, Greer J, Russell MC, Staley CA, Maithel SK. Optimal Surveillance Frequency After CRS/HIPEC for Appendiceal and Colorectal Neoplasms: A Multi-institutional Analysis of the US HIPEC Collaborative. Ann Surg Oncol. 2019 Jun.27(1):134-146. Pubmedid: 31243668. Pmcid: PMC6925634.
  • Kotha NV, Baumgartner JM, Veerapong J, Cloyd JM, Ahmed A, Grotz TE, Leiting JL, Fournier K, Lee AJ, Dineen SP, Dessureault S, Clarke C, Mogal H, Zaidi MY, Russell MC, Patel SH, Sussman JJ, Dhar V, Lambert LA, Hendrix RJ, Abbott DE, Pokrzywa C, Lafaro K, Lee B, Greer JB, Fackche N, Lowy AM, Kelly KJ. Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. Ann Surg Oncol. 2019 Jul.26(7):2234-2240. Pubmedid: 31016486.
  • Sabesan A, Felder S, Feuerlein S, Lam C, McGettigan M, Powers BD, Dessureault S, Dineen SP. Preoperative Radiographic Assessment Predicts Incomplete Cytoreduction in Patients with Low Grade Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol. 2019 Aug.27(1):165-170. Pubmedid: 31388776.
  • Wach MM, Ayabe RI, Ruff SM, D'Angelica M, Dineen SP, Grubbs EG, Shibata D, Shirley L, Weiss MJ, Davis JL, Hernandez JM. A Survey of the Complex General Surgical Oncology Fellowship Programs Regarding Applicant Selection and Rank. Ann Surg Oncol. 2019 Apr.26(9):2675-2681. Pubmedid: 31011903. Pmcid: PMC6684844.
  • Peterson SL, Husnain M, Pollack T, Pimentel A, Loaiza-Bonilla A, Westendorf-Overley C, Ratermann K, Anthony L, Desimone P, Goel G, Kudrimoti M, Dineen S, Tzeng CD, Hosein PJ. Neoadjuvant -paclitaxel and Gemcitabine in Borderline Resectable or Locally Advanced Unresectable Pancreatic Adenocarcinoma in Patients Who Are Ineligible for FOLFIRINOX. Anticancer Res. 2018 Jul.38(7):4035-4039. Pubmedid: 29970528.
  • Frohman HA, Martin JT, Le AT, Dineen SP, Tzeng CD. Failure to operate on resectable gastric cancer: implications for policy changes and regionalization. J Surg Res. 2017 Jun.214:229-239. Pubmedid: 28624049.
  • Le AT, Harris JW, Maynard E, Dineen SP, Tzeng CD. Thromboelastography demonstrates perioperative hypercoagulability in hepato-pancreato-biliary patients and supports routine administration of preoperative and early postoperative venous thromboembolism chemoprophylaxis. HPB (Oxford). 2017 Feb.19(2):154-161. Pubmedid: 27894845.
  • Dineen SP, Royal RE, Mansfield PF, Fournier KF. Comment on: External Validation of the Simplified Preoperative Assessment for Low-Grade Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol. 2017 Dec.24(Suppl 3):627. Pubmedid: 29124485.
  • Saeed H, Hnoosh D, Huang B, Durbin EB, McGrath PC, Desimone P, Maynard E, Anthony LB, Dineen SP, Hosein PJ, Tzeng CW. Defining the optimal timing of adjuvant therapy for resected pancreatic adenocarcinoma: A statewide cancer registry analysis. J Surg Oncol. 2016 Sep.114(4):451-455. Pubmedid: 27238300.
  • Roland CL, May CD, Watson KL, Al Sannaa GA, Dineen SP, Feig R, Landers S, Ingram DR, Wang WL, Guadagnolo BA, Feig B, Hunt KK, Cormier JN, Lazar AJ, Torres KE. Analysis of Clinical and Molecular Factors Impacting Oncologic Outcomes in Undifferentiated Pleomorphic Sarcoma. Ann Surg Oncol. 2016 Jul.23(7):2220-2228. Pubmedid: 26847678. Pmcid: PMC4937623.
  • Dineen SP, Robinson KA, Roland CL, Beaty KA, Rafeeq S, Mansfield PF, Royal RE, Fournier KF. Feeding tube placement during cytoreductive surgery and heated intraperitoneal chemotherapy does not improve postoperative nutrition and is associated with longer length of stay and higher readmission rates. J Surg Res. 2016 Jan.200(1):158-163. Pubmedid: 26342838.
  • Kirane A, Ludwig KF, Sorrelle N, Haaland G, Sandal T, Ranaweera R, Toombs JE, Wang M, Dineen SP, Micklem D, Dellinger MT, Lorens JB, Brekken RA. Warfarin Blocks Gas6-Mediated Axl Activation Required for Pancreatic Cancer Epithelial Plasticity and Metastasis. Cancer Res. 2015 Sep.75(18):3699-3705. Pubmedid: 26206560. Pmcid: PMC4572915.
  • Dineen SP, Royal RE, Hughes MS, Sagebiel T, Bhosale P, Overman M, Matamoros A, Mansfield PF, Fournier KF. A Simplified Preoperative Assessment Predicts Complete Cytoreduction and Outcomes in Patients with Low-Grade Mucinous Adenocarcinoma of the Appendix. Ann Surg Oncol. 2015 Oct.22(11):3640-3646. Pubmedid: 25698402. Pmcid: PMC4565864.
  • Dineen SP, Roland CL, Feig R, May C, Zhou S, Demicco E, Sannaa GA, Ingram D, Wang WL, Ravi V, Guadagnolo A, Lev D, Pollock RE, Hunt K, Cormier J, Lazar A, Feig B, Torres KE. Radiation-Associated Undifferentiated Pleomorphic Sarcoma is Associated with Worse Clinical Outcomes than Sporadic Lesions. Ann Surg Oncol. 2015 Nov.22(12):3913-3920. Pubmedid: 25743327. Pmcid: PMC4561200.
  • Dineen SP, Pham TH, Murray BW, Parker BJ, Hartless K, Anthony T, Huerta S. Feasibility of subcutaneous gentamicin and pressurized irrigation as adjuvant strategies to reduce surgical site infection in colorectal surgery: results of a pilot study. Am Surg. 2015 Jun.81(6):573-579. Pubmedid: 26031269.
  • Dineen S, Lynch PM, Rodriguez-Bigas MA, Bannon S, Taggart M, Reeves C, Modaro C, Overman M, Chang GJ, Skibber JM, You YN. A Prospective Six Sigma Quality Improvement Trial to Optimize Universal Screening for Genetic Syndrome Among Patients With Young-Onset Colorectal Cancer. J Natl Compr Canc Ne. 2015 Jul.13(7):865-872. Pubmedid: 26150580.
  • Huerta S, Pham T, Foster S, Livingston EH, Dineen S. Outcomes of emergent inguinal hernia repair in veteran octogenarians. Am Surg. 2014 May.80(5):479-483. Pubmedid: 24887727.
  • Dineen SP, Bailey SH, Pham TH, Huerta S. Clostridium difficile enteritis: A report of two cases and systematic literature review. World J Gastrointest Surg. 2013 Mar.5(3):37-42. Pubmedid: 23556059. Pmcid: PMC3615302.
  • Hakiman H, Delibero J, Pham T, Dineen S, Huerta S. Coughing-induced bowel transection in a patient with an incarcerated inguinal hernia: a case report. J Med Case Rep. 2013 Feb.7:47. Pubmedid: 23414609. Pmcid: PMC3582600.
  • Kayatta MO, Dineen SP, Sica G, Puskas JD, Pickens A. Primary pericardial mesothelioma in a 19-year-old presenting as pericarditis. Ann Thorac Surg. 2013 Aug.96(2):680-681. Pubmedid: 23353042.
  • Huerta S, Gao X, Dineen S, Kapur P, Saha D, Meyer J. Role of p53, Bax, p21, and DNA-PKcs in radiation sensitivity of HCT-116 cells and xenografts. Surgery. 2013 Aug.154(2):143-151. Pubmedid: 23889944.
  • Dineen S. Biology of rectal cancer--the rationale for targeted therapy. Crit Rev Oncog. 2012 Jan.17(4):383-392. Pubmedid: 23176045.
  • Dineen SS, McBride SM, Sonenshein AL. Integration of metabolism and virulence by Clostridium difficile CodY. J Bacteriol. 2010 Oct.192(20):5350-5362. Pubmedid: 20709897. Pmcid: PMC2950512.
  • Arnold SA, Rivera LB, Miller AF, Carbon JG, Dineen SP, Xie Y, Castrillon DH, Sage EH, Puolakkainen P, Bradshaw AD, Brekken RA. Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma. Dis Model Mech. 2010 Mar.3(1-2):57-72. Pubmedid: 20007485. Pmcid: PMC2806901.
  • Dineen SP, Roland CL, Schwarz RE. Pancreatoduodenectomy with or without pyloric preservation: a clinical outcomes comparison. Hpb Surg. 2010 Jun.2008:719459. Pubmedid: 19197376. Pmcid: PMC2633452.
  • Chambliss KL, Wu Q, Oltmann S, Konaniah ES, Umetani M, Korach KS, Thomas GD, Mineo C, Yuhanna IS, Kim SH, Madak-Erdogan Z, Maggi A, Dineen SP, Roland CL, Hui DY, Brekken RA, Katzenellenbogen JA, Katzenellenbogen BS, Shaul PW. Non-nuclear estrogen receptor alpha signaling promotes cardiovascular protection but not uterine or breast cancer growth in mice. J Clin Invest. 2010 Jul.120(7):2319-2330. Pubmedid: 20577047. Pmcid: PMC2898582.
  • Roland CL, Dineen SP, Toombs JE, Carbon JG, Smith CW, Brekken RA, Barnett CC. Tumor-derived intercellular adhesion molecule-1 mediates tumor-associated leukocyte infiltration in orthotopic pancreatic xenografts. Exp Biol Med (Maywood). 2010 Feb.235(2):263-270. Pubmedid: 20404043.
  • Murray BW, Huerta S, Dineen S, Anthony T. Surgical site infection in colorectal surgery: a review of the nonpharmacologic tools of prevention. J Am Coll Surg. 2010 Dec.211(6):812-822. Pubmedid: 20980173.
  • Ramos AL, Darabi R, Akbarloo N, Borges L, Catanese J, Dineen SP, Brekken RA, Perlingeiro RC. Clonal analysis reveals a common progenitor for endothelial, myeloid, and lymphoid precursors in umbilical cord blood. Circ Res. 2010 Dec.107(12):1460-1469. Pubmedid: 20947832.
  • Dineen SP, Roland CL, Greer R, Carbon JG, Toombs JE, Gupta P, Bardeesy N, Sun H, Williams N, Minna JD, Brekken RA. Smac mimetic increases chemotherapy response and improves survival in mice with pancreatic cancer. Cancer Res. 2010 Apr.70(7):2852-2861. Pubmedid: 20332237. Pmcid: PMC2848888.
  • Roland CL, Lynn KD, Toombs JE, Dineen SP, Udugamasooriya DG, Brekken RA. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS One. 2009 Nov.4(11):e7669. Pubmedid: 19888452. Pmcid: PMC2766251.
  • Dineen SP, Roland CL, Toombs JE, Kelher M, Silliman CC, Brekken RA, Barnett CC. The acellular fraction of stored platelets promotes tumor cell invasion. J Surg Res. 2009 May.153(1):132-137. Pubmedid: 18541268.
  • Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts. Mol Cancer Ther. 2009 Jul.8(7):1761-1771. Pubmedid: 19567820.
  • Naylor RA, Hollett LA, Valentine RJ, Mitchell IC, Bowling MW, Ma AM, Dineen SP, Bruns BR, Scott DJ. Can medical students achieve skills proficiency through simulation training?. Am J Surg. 2009 Aug.198(2):277-282. Pubmedid: 19362285.
  • Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, Wang ZV, Landskroner-Eiger S, Dineen S, Magalang UJ, Brekken RA, Scherer PE. Hypoxia-inducible factor 1alpha induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol. 2009 Aug.29(16):4467-4483. Pubmedid: 19546236. Pmcid: PMC2725728.
  • Dineen SP, Sullivan LA, Beck AW, Miller AF, Carbon JG, Mamluk R, Wong H, Brekken RA. The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer. BMC Cancer. 2008 Nov.8:352. Pubmedid: 19038046. Pmcid: PMC2627916.
  • Dineen S, Schumacher P, Thal E, Frankel H. CT reconstructions of right-sided blunt diaphragm rupture. J Trauma. 2008 May.64(5):1412. Pubmedid: 18277271.
  • Dineen SP, Lynn KD, Holloway SE, Miller AF, Sullivan JP, Shames DS, Beck AW, Barnett CC, Fleming JB, Brekken RA. Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into orthotopic pancreatic tumors in mice. Cancer Res. 2008 Jun.68(11):4340-4346. Pubmedid: 18519694.
  • Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T. A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. J Am Chem Soc. 2008 Apr.130(17):5744-5752. Pubmedid: 18386897.
  • Blumetti J, Luu M, Sarosi G, Hartless K, McFarlin J, Parker B, Dineen S, Huerta S, Asolati M, Varela E, Anthony T. Surgical site infections after colorectal surgery: do risk factors vary depending on the type of infection considered?. Surgery. 2007 Nov.142(5):704-711. Pubmedid: 17981191.
  • Dineen S, Smith S, Arko FR. Successful percutaneous angioplasty and stenting of the radial artery in a patient with chronic upper extremity ischemia and digital gangrene. J Endovasc Ther. 2007 Jun.14(3):426-428. Pubmedid: 17723011.
  • Friese RS, Dineen S, Jennings A, Pruitt J, McBride D, Shafi S, Frankel H, Gentilello LM. Serum B-type natriuretic peptide: a marker of fluid resuscitation after injury?. J Trauma. 2007 Jun.62(6):1346-1350. Pubmedid: 17563646.
  • Schumacher P, Dineen S, Barnett C, Fleming J, Anthony T. The metastatic lymph node ratio predicts survival in colon cancer. Am J Surg. 2007 Dec.194(6):827-831. Pubmedid: 18005779.
  • Chao C, Studts JL, Abell T, Hadley T, Roetzer L, Dineen S, Lorenz D, YoussefAgha A, McMasters KM. Adjuvant chemotherapy for breast cancer: how presentation of recurrence risk influences decision-making. J Clin Oncol. 2003 Dec.21(23):4299-4305. Pubmedid: 14581440.
  • Crombag HS, Badiani A, Chan J, Dell'Orco J, Dineen SP, Robinson TE. The ability of environmental context to facilitate psychomotor sensitization to amphetamine can be dissociated from its effect on acute drug responsiveness and on conditioned responding. Neuropsychopharmacology. 2001 Jun.24(6):680-690. Pubmedid: 11331148.
  • Dineen S, Withrow K, Voronovitch L, Munshi F, Nawbary MW, Lippmann S. QTc prolongation and high-dose olanzapine. Psychosomatics. 44(2):174-175. Pubmedid: 12618539.

Patient Comments
Overall Satisfaction

0 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments